ArticleFrontiers in human neuroscience2025
From early symptoms to EEG silence: tracking the neurodegenerative course of sporadic Creutzfeldt-Jakob disease.
Article in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sporadic Creutzfeldt-Jakob disease: a multidimensional review from epidemiology to treatment and prognosis.Journal of neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive and fatal neurodegenerative disorder. Early diagnosis remains challenging due to nonspecific initial symptoms. Although electroencephalography (EEG) is a key diagnostic tool, particularly through the detection of periodic sharp wave complexes (PSWCs), the longitudinal evolution of EEG features and their correlation with clinical and neuroimaging progression are not fully characterized. Methods: This retrospective cohort study analyzed 37 patients diagnosed with probable and very probable sCJD according to the 2021 Chinese diagnostic guidelines. All patients underwent at least one EEG examination. One representative patient was followed for 23 weeks with serial EEG and MRI studies to document dynamic electrophysiological and structural changes. EEG background activity was graded as mild, moderate, or severe, and PSWCs were identified based on standardized criteria. MRI analyses focused on the spatial and temporal progression of hyperintense lesions on DWI and FLAIR sequences. Results: Among the 37 patients, 46% underwent initial EEG within 1 month of symptom onset, and 49% exhibited severe background abnormalities. PSWCs were present in 84% of patients at first EEG, with a high prevalence (82%) even in those examined within 4 weeks of onset. Longitudinal analysis in the index case revealed a progressive EEG deterioration: from slowed and disorganized background rhythms and emerging triphasic waves at 8 weeks, to widespread PSWCs with increasing periodicity (9-16 weeks), and finally to a burst-suppression pattern near electrical silence by week 23. Concurrent MRI showed a parallel expansion of hyperintense lesions from unilateral cortical and basal ganglia regions to bilateral involvement, closely correlated with the EEG progression. Statistical analysis showed no significant correlation between survival time and age, time to first EEG, CSF 14-3-3 protein status, or initial EEG background grade. Furthermore, neither the presence of typical PSWCs nor the severity of background activity was associated with survival outcomes. Conclusion: EEG, especially the early and highly prevalent presence of PSWCs, offers high diagnostic value in sCJD but does not serve as prognostic predictors. The close correlation between EEG decline and MRI progression supports multimodal monitoring. Serial EEG should be integrated into sCJD diagnosis and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.